ALK and non-small cell lung carcinoma: We analyzed clinical outcomes of post-treatment after alectinib failure in ALK-rearranged NSCLC and revealed similar ORR and PFS between the PEM and LOR groups ([LOR group] mPFS = 6.2 mo, ORR = 44%; and [PEM group] mPFS = 6.9, ORR = 45%), which were consistent with previous reports.9